Repligen Corporation $RGEN Shares Sold by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB trimmed its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 15.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,600 shares of the biotechnology company’s stock after selling 5,089 shares during the quarter. E. Ohman J or Asset Management AB owned approximately 0.05% of Repligen worth $3,370,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in RGEN. Rockefeller Capital Management L.P. lifted its position in shares of Repligen by 201.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 579 shares of the biotechnology company’s stock worth $95,000 after purchasing an additional 387 shares during the last quarter. MidFirst Bank bought a new stake in Repligen in the fourth quarter valued at about $299,000. Pacer Advisors Inc. raised its stake in Repligen by 2.5% during the fourth quarter. Pacer Advisors Inc. now owns 10,469 shares of the biotechnology company’s stock valued at $1,715,000 after buying an additional 256 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Repligen by 12.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 646,122 shares of the biotechnology company’s stock valued at $105,874,000 after buying an additional 74,044 shares in the last quarter. Finally, Compound Planning Inc. bought a new position in Repligen during the 4th quarter worth approximately $204,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on RGEN shares. Jefferies Financial Group reiterated a “hold” rating and issued a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. Wells Fargo & Company reduced their price objective on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Wolfe Research started coverage on shares of Repligen in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective for the company. HC Wainwright boosted their target price on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Finally, Royal Bank Of Canada initiated coverage on shares of Repligen in a report on Thursday, May 14th. They set an “outperform” rating and a $160.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $164.64.

Repligen Price Performance

NASDAQ:RGEN opened at $132.02 on Friday. The firm has a market capitalization of $7.45 billion, a PE ratio of 146.69, a price-to-earnings-growth ratio of 2.54 and a beta of 1.09. The stock has a 50 day moving average of $121.68 and a 200-day moving average of $136.56. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $175.77. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The business had revenue of $194.25 million for the quarter, compared to analysts’ expectations of $192.05 million. During the same period in the prior year, the firm earned $0.39 EPS. The business’s quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Analysts predict that Repligen Corporation will post 1.99 EPS for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.